DIRS.INFO The most relevant business & tech news

☆ Wells Fargo sees this biotech stock rallying 75% in its bull case
▼ + stars: | 2024-12-02 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

The success of one of Kymera Therapeutics' experimental treatments could mean more upside ahead for the stock, Wells Fargo found. Analyst Derek Archila upgraded shares to overweight from equal weight and upped his price target by $19 to $57, which implies more than 21% upside from Friday's close. KYMR YTD mountain KYMR, year-to-date The analyst pointed to Kymera's oral treatment for multiple immuno-inflammatory diseases. He anticipates the data will likely demonstrate a "clean" safety profile, and his bull case scenario forecasts shares could trade higher by 75%. Kymera also has a consensus price target of $57.88, which reflects more than 20% upside from current levels.

Persons: Wells, Derek Archila, Archila, Kymera Organizations: Therapeutics, KT Locations: Wells Fargo

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Gap, Block, Marvell, Okta, Netflix, Dell & more
▼ + stars: | 2024-12-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Cantor Fitzgerald reiterates Marvell & Nvidia as top picks Cantor says both stocks remain top picks ahead of Marvell earnings on Tuesday. Goldman Sachs initiates Venom Energy as buy Goldman says it sees "strong shareholder returns" for the energy company. Goldman Sachs downgrades Toast to neutral from buy Goldman says the thesis has played out for the restaurant tech company. Goldman Sachs initiates Ero Copper as buy Goldman says the copper company has a "unique growth profile." Roth MKM upgrades Tesla to buy from neutral Roth said in its upgrade of Tesla that the "world has changed."

Persons: Cantor Fitzgerald, Cantor, it's bullish, Morgan Stanley, Goldman Sachs, Goldman, Stifel, Tesla, Bernstein, Block, Dana, AAPL, Stryker, We'd, Wells, Roth, Dell Organizations: Netflix, Marvell, Nvidia, MU, UBS, Caci International, DHS, AutoDesk, Autodesk, Architective, NET, Energy, Viper Energy, JPMorgan, Air Lease, Burlington, Barclays, NextEra Energy Partners, KT, Deutsche Bank, DELL Locations: France, Germany, AVGO, Cleveland, TOST, Burlington

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

☆ A biotech hedge fund that counts Yale’s endowment among its clients bought a new stake in this genetic testing company
▼ + stars: | 2023-08-16 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing. The biotech stock with a focus on neuroscience has surged more than 84% this year. Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%. The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%. The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.

Persons: Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li Organizations: Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics Locations: InVitae, Invitae, Acadia, ImmunoGen

☆ These are the top 10 stock plays for 2023, according to UBS
▼ + stars: | 2022-12-14 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +5 min

As the year winds down, investors are looking forward to 2023 and wondering where they should place their top bets. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023. The stock which is poised for the largest gain is Kymera Therapeutics , a biotechnology firm that UBS thinks could surge 240% to its target price. She added that UBS expects updates across all four programs in the near term as well as over 2023. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023.

There is no evidence that any school has deployed litter boxes for students to use because they identify as cats. The rumor of litter boxes in schools appears to have begun among parents on social media, and one of the first schools to confront the falsehood was in Canada last fall. Catalina Lauf, a Republican congressional nominee in Illinois, tweeted this month that schoolchildren were using litter boxes in her state. Some say litter boxes are located in “transgender bathrooms” in schools. Meanwhile on TikTok, one video claiming “kids are now requesting litter boxes at school” collected 3 million views on the platform.

Search resuls for: "Kymera"

6 mentions found